Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Crame.

Yesterday, March 10, 2015, 98 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,617.00 to $5,999,989.08.

Highlighted Stocks Traded by Insiders:

Enanta Pharmaceuticals (ENTA) - FREE Research Report

Luly Jay R., who is President and CEO at Enanta Pharmaceuticals, sold 15,000 shares at $33.37 on March 10, 2015. Following this transaction, the President and CEO owned 476,393 shares meaning that the stake was reduced by 3.05% with the 15,000-share transaction.

The shares most recently traded at $34.29, up $0.92, or 2.69% since the insider transaction. Historical insider transactions for Enanta Pharmaceuticals go as follows:

  • 4-Week # shares bought: 2,400
  • 4-Week # shares sold: 15,000
  • 12-Week # shares bought: 2,400
  • 12-Week # shares sold: 34,500
  • 24-Week # shares bought: 2,400
  • 24-Week # shares sold: 74,500

The average volume for Enanta Pharmaceuticals has been 408,400 shares per day over the past 30 days. Enanta Pharmaceuticals has a market cap of $631.4 million and is part of the health care sector and drugs industry. Shares are down 33.53% year-to-date as of the close of trading on Tuesday.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States. The company has a P/E ratio of 7.9. Currently, there are 3 analysts who rate Enanta Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENTA - FREE

TheStreet Quant Ratings

rates Enanta Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full

Enanta Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

John Bean Technologies (JBT) - FREE Research Report

Montague Mark K, who is EVP, Human Resources at John Bean Technologies, sold 3,000 shares at $33.74 on March 10, 2015. Following this transaction, the EVP, Human Resources owned 40,035 shares meaning that the stake was reduced by 6.97% with the 3,000-share transaction.

Smith Steven R, who is EVP & President, JBT FoodTech at John Bean Technologies, sold 3,000 shares at $34.00 on March 10, 2015. Following this transaction, the EVP & President, JBT FoodTech owned 64,748 shares meaning that the stake was reduced by 4.43% with the 3,000-share transaction.

The shares most recently traded at $33.36, down $0.64, or 1.93% since the insider transaction. Historical insider transactions for John Bean Technologies go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 7,000
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 7,000
  • 24-Week # shares bought: 3,000
  • 24-Week # shares sold: 7,000

The average volume for John Bean Technologies has been 97,000 shares per day over the past 30 days. John Bean Technologies has a market cap of $996.5 million and is part of the industrial goods sector and industrial industry. Shares are up 1.86% year-to-date as of the close of trading on Tuesday.

John Bean Technologies Corporation provides technology solutions for the food processing and air transportation industries. The stock currently has a dividend yield of 1.06%. The company has a P/E ratio of 33.0. Currently, there is 1 analyst who rates John Bean Technologies a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on JBT - FREE

TheStreet Quant Ratings

rates John Bean Technologies as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, good cash flow from operations, increase in net income and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

John Bean Technologies Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

NuVasive (NUVA) - FREE Research Report

Hannon Jason, who is EVP, General Counsel & Sec. at NuVasive, sold 3,615 shares at $44.67 on March 10, 2015. Following this transaction, the EVP, General Counsel & Sec. owned 44,273 shares meaning that the stake was reduced by 7.55% with the 3,615-share transaction.

The shares most recently traded at $44.83, up $0.16, or 0.36% since the insider transaction. Historical insider transactions for NuVasive go as follows:

  • 4-Week # shares sold: 23,278
  • 12-Week # shares sold: 33,963
  • 24-Week # shares sold: 41,463

The average volume for NuVasive has been 389,400 shares per day over the past 30 days. NuVasive has a market cap of $2.2 billion and is part of the health care sector and health services industry. Shares are down 4.56% year-to-date as of the close of trading on Tuesday.

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. Currently, there are 11 analysts who rate NuVasive a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NUVA - FREE

TheStreet Quant Ratings

rates NuVasive as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow. Get the full

NuVasive Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null